AstraZeneca has lost a second senior executive in a two-week span with the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of lung drug specialist Vectura.
His departure follows the exit earlier this month of Briggs Morrison, AstraZeneca’s former chief medical officer and head of late-stage drug development, who moved on to become CEO of privately owned cancer drug firm Syndax.
The move is a blow to AstraZeneca, which has identified respiratory medicine as one of its six growth businesses.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive